Cyclin-Dependent Kinase Inhibitor Pipeline Accelerates as 45+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight's, "Cyclin-Dependent Kinase Inhibitor Pipeline Insights 2026" report provides comprehensive insights about 45+ companies and 52+ pipeline drugs in Cyclin-Dependent Kinase Inhibitor pipeline landscape. It covers the Cyclin-Dependent Kinase Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cyclin-Dependent Kinase Inhibitor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Cyclin-Dependent Kinase Inhibitor Research @ https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Cyclin-Dependent Kinase Inhibitor Pipeline Report
• In August 2026, Antares Therapeutics initiated a first-in-human Phase I/II clinical trial of ATX-898 in patients with advanced solid tumors, exploring the investigational therapy alongside CDK4/6 inhibitors in breast cancer.
• In June, 2026- Alliance for Clinical Trials in Oncology initiated a phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
• In May, 2026- Eli Lilly and Company conducted a phase 2 study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.
• In May, 2026- Pfizer announced a study will assess the safety and tolerability of increasing dose levels of PF-07104091 in Part 1, and establish the recommended Phase 2 dose (RP2D) in Part 2. A study C4161001 is a Phase 1, open label, multi dose, multi center, dose escalation, safety, pharmacokinetic (PK) and pharmacodynamic study of PF-07104091 in adult patients with advanced or metastatic small cell lung cancer (SCLC), advanced platinum resistant epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer, locally recurrent/advanced or metastatic triple negative breast cancer (TNBC), HR-positive HER2-negative advanced or mBC, advanced or metastatic non-small cell lung cancer (NSCLC).
• DelveInsight's Cyclin Dependent Kinase Inhibitor pipeline report depicts a robust space with 45+ active players working to develop 52+ pipeline therapies for Cyclin Dependent Kinase Inhibitor treatment.
• The leading Cyclin Dependent Kinase Inhibitor Companies such as G1 Therapeutics, Betta Pharmaceuticals Co Ltd, Eli Lilly and Company, Pfizer, Tiziana Life Sciences LTD, GenFleet Therapeutics, Vincerx Pharma, Syros Pharmaceuticals, BeyondBio, Kronos Bio, Qurient Co, Sumitomo Pharma, OnKure Therapeutics, Biolexis Therapeutics, InSilico Medicine, Avenzo Therapeutics and others.
• Promising Cyclin Dependent Kinase Inhibitor Therapies such as Palbociclib PD-0332991, Abemaciclib, Anastrozole, Letrozole, Vismodegib, and others.

Stay informed about the cutting-edge advancements in Cyclin-Dependent Kinase Inhibitor treatments @ https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cyclin-Dependent Kinase Inhibitor Overview
Cyclin-dependent kinase inhibitor protein (also known as CKIs, CDIs, or CDKIs) is a protein which inhibits the enzyme cycling-dependent kinase (CDK) and Cyclin activity by stopping the cell cycle if there are unfavorable conditions, therefore, acting as tumor suppressors. Cell cycle progression is stopped by Cyclin-dependent kinase inhibitor protein at the G1 phase. CKIs are vital proteins within the control system that point out whether the process of DNA synthesis, mitosis, and cytokines control one another. If a malfunction prevents the successful completion of DNA synthesis during the G1 phase, a signal is sent to delay or stop the progression to the S phase. Cyclin-dependent kinase inhibitor proteins are essential in the regulation of the cell cycle. If cell mutations surpass the cell cycle checkpoints during cell cycle regulation, it can result in various types of cancer.

Cyclin-Dependent Kinase Inhibitor Emerging Drugs Profile
• Abemaciclib: Eli Lilly and Company
Abemaciclib selectively inhibits CDK4 and CDK6 with low nanomolar potency. These enzymes are responsible for phosphorylating and thus deactivating the retinoblastoma protein, which plays a role in cell cycle progression from the G1 (first gap) to the S (synthesis) phase. Blocking this pathway prevents cells from progressing to the S phase, thereby inducing apoptosis (cell death). In vitro analysis using cancer cell lines shows that abemaciclib induces non‐apoptotic cell death characterized by the formation of cytoplasmic vacuoles derived from lysosomes. The drug was approved for use in combination with endocrine therapy (such as tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. Currently, the drug is in the Phase III stage of its development for the treatment of Liposarcoma and Prostate cancer.

• GFH-009: GenFleet Therapeutics/ Sellas Life Sciences Group
GFH009 is a potent and highly selective small-molecule inhibitor of CDK9 with more than 100 times selectivity over other CDK subtypes. Preclinical data have also suggested the potential anti-tumor effects of GFH009 in combination with BCL-2 inhibitors. As a potent and highly selective small molecule CDK9 inhibitor, GFH009 exhibits strong apoptosis-inducing and anti-proliferative activities in multiple human cell lines and animal models of diseases. It effectively inhibits the growth of tumor in various xenograft models and significantly improves survival of tumor bearing animals. The drug is currently in Phase II stage of Clinical trial evaluation for the treatment Hematological malignancies.

• Enitociclib: Vincerx Pharma
Enitociclib is a potent and selective CDK9 inhibitor currently in clinical development. The small molecule inhibitor targets P-TEFb/CDK9 and has shown robust pathway modulation as well as efficacy and safety in several preclinical tumor models and in early phase clinical studies. Enitociclib was identified as a top hit in small molecule inhibitor screening and exposure to Enitociclib for 96 hours against a representative panel of MM cell lines (NCI-H929, MM.1S, OPM-2, and U266B1) demonstrated significant cytotoxic activity, with IC50 values ranging from 36 to 78 nM. Vincerx Pharma is focused on Phase I/II study with the National Institutes of Health (NIH) evaluating combination of Enitociclib and Venetoclax and prednisone (VVIP) in diffuse large B-cell lymphoma (DLBCL) and peripheral T Cell Lymphoma (PTCL).

• AVZO-021: Avenzo Therapeutics Inc.
AVZO-021, also known as ARTS-021, is a promising clinical-stage drug developed by Avenzo Therapeutics, Inc. It is a highly potent and selective inhibitor of cyclin-dependent kinase 2 (CDK2), primarily aimed at treating hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, as well as cancers with cyclin E1 (CCNE1) amplification. Currently, the drug is in the Phase I/II stage of its development for the treatment of triple negative breast cancer.

The Cyclin-Dependent Kinase Inhibitor Pipeline Report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Cyclin-Dependent Kinase Inhibitor with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cyclin-Dependent Kinase Inhibitor Treatment.
• Cyclin-Dependent Kinase Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cyclin-Dependent Kinase Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cyclin-Dependent Kinase Inhibitor market.

Learn more about Cyclin-Dependent Kinase Inhibitor Drugs opportunities in our groundbreaking research @ https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cyclin-Dependent Kinase Inhibitor Companies
G1 Therapeutics, Betta Pharmaceuticals Co Ltd, Eli Lilly and Company, Pfizer, Tiziana Life Sciences LTD, GenFleet Therapeutics, Vincerx Pharma, Syros Pharmaceuticals, BeyondBio, Kronos Bio, Qurient Co, Sumitomo Pharma, OnKure Therapeutics, Biolexis Therapeutics, InSilico Medicine, Avenzo Therapeutics and others.

Cyclin-Dependent Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Cyclin-Dependent Kinase Inhibitor Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in Cyclin-Dependent Kinase Inhibitor treatment by visiting our website @ https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Cyclin-Dependent Kinase Inhibitor Pipeline Report
• Coverage- Global
• Cyclin-Dependent Kinase Inhibitor Companies- G1 Therapeutics, Betta Pharmaceuticals Co Ltd, Eli Lilly and Company, Pfizer, Tiziana Life Sciences LTD, GenFleet Therapeutics, Vincerx Pharma, Syros Pharmaceuticals, BeyondBio, Kronos Bio, Qurient Co, Sumitomo Pharma, OnKure Therapeutics, Biolexis Therapeutics, InSilico Medicine, Avenzo Therapeutics and others.
• Cyclin Dependent Kinase Inhibitor Therapies- Palbociclib PD-0332991, Abemaciclib, Anastrozole, Letrozole, Vismodegib, and others.
• Cyclin-Dependent Kinase Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cyclin-Dependent Kinase Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Cyclin-Dependent Kinase Inhibitor Pipeline on our website @ https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-inhibitor-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Cyclin-Dependent Kinase Inhibitor : Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cyclin-Dependent Kinase Inhibitor - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Abemaciclib: Eli Lilly and Company
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. GFH-009: GenFleet Therapeutics/ Sellas Life Sciences Group
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. Product Name: Company Name
15. Preclinical Stage Products
16. Drug Name: Company Name
17. Drug profiles in the detailed report.....
18. Inactive Products
19. Cyclin-Dependent Kinase Inhibitor Key Companies
20. Cyclin-Dependent Kinase Inhibitor Key Products
21. Cyclin-Dependent Kinase Inhibitor- Unmet Needs
22. Cyclin-Dependent Kinase Inhibitor- Market Drivers and Barriers
23. Cyclin-Dependent Kinase Inhibitor- Future Perspectives and Conclusion
24. Cyclin-Dependent Kinase Inhibitor Analyst Views
25. Cyclin-Dependent Kinase Inhibitor Key Companies
26. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.